A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT 06422520 Brief Summary This is a first-in-human, Phase 1a/1b study to…
Read more arrow_forwardNCT 06422520 Brief Summary This is a first-in-human, Phase 1a/1b study to…
Read more arrow_forwardNCT 06914128 Brief Summary The study treatment, BAY 3713372, is under development…
Read more arrow_forwardNCT 07016490 Brief Summary This study is an open-label phase I study…
Read more arrow_forwardACTRN 12623000956606 Brief Summary This study will be conducted in two parts…
Read more arrow_forwardNCT 06384352 Brief Summary This is a multicenter, open-label, Phase 1 study.…
Read more arrow_forwardNCT 05094336 Brief Summary The primary objective of Parts 1 and 2…
Read more arrow_forwardNCT 06669975 Brief Summary This is a Phase 1/2, multi-regional, multi-center, open-label,…
Read more arrow_forwardNCT 06130553 Brief Summary This is a first time in human (FTiH)…
Read more arrow_forwardNCT 06803680 Brief Summary The goal of this clinical trial is to…
Read more arrow_forwardNCT 05410145 Brief Summary This is a first-in-human (FIH), multicenter, open-label, dose-escalation,…
Read more arrow_forward